Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe that imvotamab may have clear advantages over CAR-T therapies in autoimmune disease in terms of safety, cost and logistics |
| But again, in terms of a pharmacodynamic marker, we think it's very, very positive and very informative |
| We also saw encouraging progression-free survival in third and fourth line patients with one patient continuing for over a year without progression |
| We're very excited about the progress that we hope to make in 2023 towards our goal of bringing new and important treatments to patients |
| We are encouraged by the expanded safety and efficacy data for imvotamab at a 100 milligrams that we have developed through our clinical studies in non-Hodgkin's lymphoma, and we believe that imvotamab safety profile may be an important differentiating factor in the exciting new field of T-cell engagers in autoimmune disease |
| And so, the most important information is that it's telling us that the signal of engagement in modulating the extrinsic apoptotic product pathway is quite strong at 10 milligrams per kilogram |
| In combination with these strong signs of clinical activity, we believe that imvotamab safety profile will be an important differentiating factor in the treatment of autoimmune diseases with T-cell engagers together with the potential to more effectively deplete pathogenic B-cell deep within tissues that may be refractory to current therapies |
| We are fortunate to be in a strong financial position |
| So our hope is that imvotamab will deliver that level of deep B-cell depletion that was suggested by the CAR-T data, but do so with an off-the-shelf product, with a better safety profile, clearly lower cost and fewer logistical considerations, so we're quite excited and moving quickly |
| And we think we're in a – we have the potential to be in a real leadership position here |
| As you mentioned, we are announcing some encouraging safety and clinical activity data for imvotamab, which we think could offer a compelling and differentiated profile in the exciting new area of T-cell engagers in autoimmune disease |
| We are pleased with the safety in clinical activity profile that we have seen with imvotamab at 100 milligrams in our non-Hodgkin's lymphoma clinical studies to date, and we are excited to move forward aggressively in developing imvotamab for multiple autoimmune diseases |
| So it's an exciting place to be |
| As we are thinking about our T-cell engager assets morph through a portfolio lens than individual opportunities, and we are very excited about how these assets may come together to afford multiple therapeutic approaches to treating B-cell and plasma cell mediated diseases |
| In terms of where we might take this, again our strong interest in birinapant in this combination was really built on the preclinical models that showed strong synergy as well as the scientific, mechanistic understanding of how a SMAC mimetic could obviously combine very well with a stimulator agonist of the extrinsic apoptotic pathway |
| I am pleased to announce that we have now dosed more than 100 patients with IGM-8444 in our broad multi-indication, multi-combination Phase 1 study, and we’re very excited about the safety and clinical activity profile that we’ve seen to date in our combination with the standard FOLFIRI chemotherapy regimen in colorectal cancer patients |
| Chris Takimoto Very encouraging, as Michael, as you know, with those two agents, we are hitting both the extrinsic apoptotic pathway and the intrinsic apoptotic pathway |
| Those are the things that really got us excited |
| So, I think that strategically finding a partner that was looking to join us to explore this really new opportunity of T cell engagers and autoimmune disease, would be a really good thing for us as a company |
| We are very pleased with the data we have seen from those clinical development efforts as we announced in January of this year |
| It is something we would potentially leave open, but at least in our thinking today, we’re really pleased with what we’re seeing at 3 milligrams per kilogram |
| But long term, I think, the opportunities are so large and so many different things we could do, I think, a partner would be a really good idea for that franchise if you will |
| We are very excited by the potential for IGM-2644 to provide the next generation form of an anti-CD8 therapy |
| We are announcing today that we've successfully dosed our first two patients with no drug related safety issues |
| As I think back to the conversations that were taking place, as our company contemplated the choice of continued investment in NHL versus beginning to invest in autoimmunity, you heard the key points of that rationale earlier in the presentation given the level of competition, given the change in the regulatory and therefore the commercial environment in the lymphoma space, right? The upside on the autoimmune front, again given that this is a well-characterized target and one that could absolutely benefit from deeper B-cell depletion |
| But what is really exciting is, as Chris mentioned, is we do see with the treatment of FOLFIRI, particularly 5FU and irinotecan, you get the synergy, but you also get upregulation of DR5, which may combine well and set us up for success with IGM-8444 treatment |
| We think there is an important opportunity to bring forward a readily accessible therapy that offers deeper B-cell depletion than achievable with currently available anti-CD20 therapies |
| Also, you may recall hearing about some recent very encouraging data using CAR-T cells for B-cell depletion in lupus |
| And we think our safety is perhaps the most important differentiating factor |
| We are hopeful that this randomized study will show a significant improvement in progression-free survival relative to the standard-of-care chemotherapy control arm |
| Statement |
|---|
| Our net loss for the fourth quarter of 2022 was $52.6 million or a loss of $1.19 per share |
| For the full year 2022, our net loss was $221.1 million or a loss of $5.32 per share |
| And then also on the same agent now that you’re focusing more on the 10 milligram dose, is there a risk of seeing some of the liver issues that we’re seeing with other agents targeting – the target? Chris Takimoto Joel, what I would say is again, based on our monotherapy experience, we did not see any dose related issues |
| So in summary, a lot of activity and we await that human data |
| I will note, however that even as we await those initial human data in multiple myeloma with 2644 |
| As a result, we are announcing today that we are redirecting our clinical development efforts for imvotamab to autoimmune diseases and that we have decided to cease further monotherapy clinical development efforts for imvotamab in non-Hodgkin's lymphoma |
Please consider a small donation if you think this website provides you with relevant information